Lipocine (NASDAQ:LPCN) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

Shares of Lipocine Inc. (NASDAQ:LPCN) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.58 and traded as low as $2.01. Lipocine shares last traded at $2.05, with a volume of 95,897 shares trading hands.

Analyst Upgrades and Downgrades

LPCN has been the subject of several analyst reports. Wall Street Zen cut Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. HC Wainwright reissued a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $15.00.

Lipocine Stock Performance

The company has a 50-day moving average price of $2.63 and a 200-day moving average price of $5.58. The firm has a market capitalization of $16.89 million, a price-to-earnings ratio of -1.09 and a beta of 0.48.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. On average, research analysts expect that Lipocine Inc. will post -1.91 earnings per share for the current fiscal year.

Insider Transactions at Lipocine

In other news, CEO Mahesh V. Patel bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was purchased at an average cost of $2.03 per share, with a total value of $50,750.00. Following the transaction, the chief executive officer directly owned 160,679 shares in the company, valued at $326,178.37. This trade represents a 18.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John W. Higuchi bought 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 7th. The stock was purchased at an average cost of $2.03 per share, with a total value of $81,200.00. Following the completion of the transaction, the director owned 203,797 shares in the company, valued at approximately $413,707.91. This trade represents a 24.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders purchased 213,000 shares of company stock valued at $434,600. Insiders own 6.35% of the company’s stock.

Institutional Trading of Lipocine

A number of large investors have recently made changes to their positions in the company. Squadron Capital Management LLC acquired a new stake in shares of Lipocine in the 4th quarter valued at about $4,256,000. Eversept Partners LP purchased a new stake in Lipocine during the 1st quarter valued at approximately $2,357,000. Diadema Partners LP purchased a new stake in Lipocine during the 4th quarter valued at approximately $2,095,000. AIGH Capital Management LLC purchased a new stake in Lipocine during the 1st quarter valued at approximately $1,598,000. Finally, Ikarian Capital LLC purchased a new stake in Lipocine during the 4th quarter valued at approximately $1,602,000. 9.11% of the stock is owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.